Page 275 of 1,036: studies 2,741 to 2,750 of 10,358, newest first. Back to the depression overview
Psychiatry and Clinical Neurosciences June 19, 2018 R. Pérez-Esparza, T. Corona, R. Ruiz-García et al.
Growing evidence of the rapid antidepressant effects of ketamine represents a promising advance in treatment-resistant depression (TRD) therapeutics. Most studies provide information after treatment washout, reporting response up to 7 days and remission up to 3-5 days after a single dose.
Psychological Medicine June 15, 2018 Fernanda Palhano-Fontes, Dayanna Barreto, Heloisa Onias et al. 827 citations
Abstract Background Recent open-label trials show that psychedelics, such as ayahuasca, hold promise as fast-onset antidepressants in treatment-resistant depression. Methods To test the antidepressant effects of ayahuasca, we conducted a parallel-arm, double-blind randomized placebo-controlled trial in 29 patients with treatment-resistant depression. Patients received a single dose of either...
Neuron June 6, 2018 Daesoo Kim, Eunji Cheong, Hee-Sup Shin
The N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine has been found to have rapid and long-lasting antidepressive effects. Two elegant studies from Hailan Hu's laboratory (Cui et al., 2018; Yang et al., 2018) showed that ketamine blocks burst firing of neurons in the lateral habenula (LHb), rapidly relieving symptoms of depression.
Personality and Individual Differences June 1, 2018 Wei Xu, Xu Ding, P. Goh et al.
Abstract This study explored whether dispositional mindfulness moderated the relationship between depression and posttraumatic growth. A total of 435 Chinese adolescents who experienced a tornado in Yancheng city reported their level of depressive symptoms (The Center for Epidemiologic Studies Depression Scale for Children; CES-DC), posttraumatic growth (Posttraumatic Growth Inventory; PTGI)...
Neuropsychiatric Disease and Treatment June 1, 2018 Meagan B. MacKenzie, Kayleigh A. Abbott, Nancy L. Kocovski 69 citations
Mindfulness-based cognitive therapy (MBCT) was developed to prevent relapse in individuals with depressive disorders. This widely used intervention has garnered considerable attention and a comprehensive review of current trends is warranted. As such, this review provides an overview of efficacy, mechanisms of action, and concludes with a discussion of dissemination. Results provided strong...
Neuropsychiatric Disease and Treatment June 1, 2018 Dušan Kolar 38 citations
Treatment-resistant mood disorders and anxiety disorders require intensive treatment, but treatment options should balance benefits and adverse effects or other potential detrimental effects on patients, including the risk of developing prescription medication addiction. Some of the newer treatment modalities for mood and anxiety disorders may have similar properties to benzodiazepines. The...
International Journal of Indian Psychology May 29, 2018
Introduction: the present study was conducted with the aim of examining the effectiveness of mindfulness-based stress reduction program and conscious yoga on state and trait anxiety and depression in high school girl students. Methods: The study was quasi-experimental with pre-test, post-test, control group and a 2-month follow-up. 24 high school girl students who referred to clues all of the...
arXiv Preprint Archive May 29, 2018 Zehong Cao, Chin-Teng Lin, Weiping Ding et al. preprint
This study explores the responses to ketamine in patients with treatment-resistant depression (TRD) using a wearable forehead electroencephalography (EEG) device. We recruited fifty-five outpatients with TRD who were randomised into three approximately equal-sized groups (A: 0.5 mg/kg ketamine; B: 0.2 mg/kg ketamine; and C: normal saline) under double-blind conditions. The ketamine responses...
University Library Heidelberg May 28, 2018 Adrian Spremberg 2 citations
This article will discuss how the ‘enactive’ approach to cognition and psychological processes can help further clarifying and developing a more heuristic framework for the understanding of severe mental disorders, in this case, depression and schizophrenia. Furthermore, enactivismwill serve as a framework that comprehends depressions and schizophrenia as disorders that encompass three...
F1000Research May 24, 2018 Ronald S. Duman 203 citations
Therapeutic medications for the treatment of depression have serious limitations, particularly delayed onset and low rates of efficacy. However, the discovery that a single subanesthetic dose of ketamine, a glutamate NMDA receptor channel blocker, can produce a rapid (within hours) antidepressant response that is sustained (about 1 week), even in patients considered treatment-resistant, has...